HR1193-117 · 117th Congress
Signed
Signed Dec 20, 2022Cardiovascular Advances in Research and Opportunities Legacy Act
Cardiovascular Advances in Research and Opportunities Legacy Act This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart. The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly. The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.
LOBBYING ON THIS BILL
16 federal lobbying reports name this bill in their activity descriptions · LDA disclosures
FLUOR CORPORATION9 reports
EDWARDS LIFESCIENCES LLC7 reports
⟳ The revolving door — lobbyists on this bill with disclosed former government roles
Brian LooserPol. Ad. (Sen. Bill Cassidy, LA) LD (Rep. John Shimkus, IL-15) Sr Policy Advisor (Sen. Mark Kirk, IL) LA (Rep. Judy Biggert, IL-13) Leg. Corr./LA (Rep. Michele Bachmann, MN-06) Staff Asst./Leg. Corr.(Rep. Dennis Hastert, IL-14)
Nathan RobinsonProfessional Staff, Senate Appropriations; Associate Administrator for Congressional Affairs, FTA, DOT; Director of Congressional Affairs, FRA, DOT.
“Covered position” is the former government job lobbyists must disclose by law (LDA §4). Prior service is stated on the filings; it carries no implication of wrongdoing. Full revolving-door board →
A report naming a bill means the organization disclosed lobbying activity on it — the disclosure does not state a position for or against.
VOTE BREAKDOWN
No recorded floor vote
Most bills never receive a recorded roll-call vote — they're referred to committee and don't advance to the floor. The sponsor and funding context on this page still tells you who is behind it and what industries have a stake.
SPONSORS
Andy Barr
R-KY · Primary
125 COSPONSORS
BIPARTISAN● 47 D● 78 R
SPONSOR FUNDING
Top industries funding Barr
Securities & Investment20%
Securities & Investment 20% of classified donations
Commercial Banks15%
Commercial Banks 15% of classified donations
Lawyers & Lobbyists14%
Lawyers & Lobbyists 14% of classified donations
Insurance10%
Insurance 10% of classified donations
Real Estate6%
Real Estate 6% of classified donations
TRAIL AI
HR 1193, the Cardiovascular Advances in Research and Opportunities Legacy Act, was introduced by Representative Andy Barr of Kentucky and addresses cardiovascular disease research and related health initiatives. The bill has been signed into law. Vote data from the legislative process is not yet available.
Based on public voting records. Does not imply causation.
TIMELINE
INTRODUCEDFeb 22, 2021
PASSED SENATEDec 1, 2022
SIGNEDDec 20, 2022
DATA SOURCES
Bill data: Congress.gov · 117th–119th Congress (2021–present)
Vote records: House Clerk / Senate · 2021–present
Reflects public records. Does not imply causation.